December 20, 2016
Via: CNBCShares of Clovis Oncology closed up 8.82 percent Monday as the company received early approval for its advanced ovarian cancer drug Rubraca (rucaparib). The stock was initially up 15 percent to $42.86 before being halted for volatility. After reopening, it […]
March 28, 2024
April 19, 2024
Copyright © 2024. All rights reserved
